September 28, 2016

# Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress

## Broad Range of Presentations Includes Oncotype SEQ™ Liquid Biopsy Analytical Validation, New Outcomes Data in Invasive Breast Cancer and Studies in Node-positive Disease

REDWOOD CITY, Calif., Sept. 28, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from nine studies at the European Society for Medical Oncology (ESMO) 2016 Congress, which will take place October 7-11 at the Bella Center in Copenhagen, Denmark. The results will include:

- Analytical validation study results for the recently launched Oncotype SEQ™ Liquid Select test. Oncotype SEQ is the first non-invasive liquid biopsy test that the company is delivering through its Oncotype IQ™ Genomic Intelligence Platform.
- Two presentations highlighting updated prospective outcomes from a large population-based observational study based on the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI). The primary SEER Registry study results, published in *Nature Partner Journals Breast Cancer*, demonstrated that the Oncotype DX® Breast Recurrence Score™ accurately predicted prospective patient outcomes in more than 44,500 patients, including those with node-negative and node-positive breast cancer. The updated results to be presented at ESMO will include an additional year of patient data and an additional year of follow-up for patients included in the original study.
- New prospective outcomes data on the Oncotype DX Breast Recurrence Score from a multi-center study in node-positive disease from Clalit Health Services, the largest health maintenance organization in Israel.
- Five international studies demonstrating the value of the Oncotype DX Breast Recurrence Score on treatment decisions in Canada, the Czech Republic, Italy and Spain. These studies include new prospective clinical utility evidence for node-positive disease and results on the clinical impact of Oncotype DX beyond immunohistochemistry for Ki-67.

The ESMO abstracts are now available at www.esmo.org. Following are details for each presentation (all times are in Central European Summer Time):

**Friday, October 7**

- **Abstract:** 146 O
  **Proffered Paper Session:** "Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)"
  **Author:** S. Shak, M.D.
  **Location:** Stockholm
  **Time:** 16:00 - 17:30

**Saturday, October 8**

- **Abstract:** 147 PD
  **Poster Discussion Session:** "First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene Recurrence Score result"
  **Authors:** S. Stemmer, M.D.
  **Location:** Berlin
  **Time:** 15:00 - 16:00

- **Abstract:** 150 PD
  **Poster Discussion Session:** "Breast cancer-specific survival in > 4,600 patients with lymph node-positive (LN+) hormone receptor-positive (HR+) invasive breast cancer (BC) and 21-gene Recurrence Score (RS) results in the SEER registries"

**Authors:** D.P. Miller
**Location:** Berlin
**Time:** 15:00 - 16:00

**Monday, October 10**

- **Abstract:** 175 P
  **Poster Display:** "First prospective multicenter Italian study on the impact of the 21-gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer patients"
  **Author:** M.V. Dieci
  **Location:** Hall E
  **Session Time:** 13:00 - 14:00

- **Abstract:** 181 P
  **Poster Display:** "Budget impact analysis of the 21-gene assay (Oncotype DX Breast Cancer) for the breast cancer treatment in the Basque country"
  **Author:** Toribio, M.D.
  **Location:** Hall E
  **Session Time:** 13:00 - 14:00

- **Abstract:** 177 P
  **Poster Display:** "The impact of the 21-gene assay in the Czech Republic on adjuvant chemotherapy (CT) recommendations and costs in estrogen receptor positive (ER+) early stage breast cancer (ESBC) patients with grade 2 tumors and risk factors"
  **Author:** K. Petrakova, M.D., Ph.D.
  **Location:** Hall E
  **Session Time:** 13:00 - 14:00

- **Abstract:** 180 P
  **Poster Display:** "Use of Oncotype DX Recurrence Score (RS) reduces chemotherapy (CT) beyond treatment decisions using Ki67-based determinations of luminal A and B breast cancer subtypes: A retrospective study in the Spanish population"
  **Author:** L. Garcia-Estevez, M.D.
  **Location:** Hall E
  **Session Time:** 13:00 - 14:00

- **Abstract:** 183 P
  **Poster Display:** "Prospective evaluation of the impact of the 21-gene Recurrence Score assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada"
  **Author:** S. Torres, M.D.
  **Location:** Hall E
  **Session Time:** 13:00 - 14:00

- **Abstract:** 1162 P
  **Poster Display:** "Analytical performance of a new liquid biopsy mutation panel for detection of clinically actionable variants"
  **Author:** C. Svedman, M.D.
  **Location:** Hall E
  **Session Time:** 13:00 - 14:00

**About Oncotype DX®**

The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the

unique biology of a tumor in order to optimize cancer treatment decisions. With more than 600,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.

**About Genomic Health**

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ™ Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 600,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ™ Liquid Select assay. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties are set forth in our filings with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q for the quarter ended June 30, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.*



GHDX-B